OncXerna Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
OncXerna Therapeutics (formerly Oncologie), founded in 2018 by Laura Benjamin, was a precision oncology company. It built an RNA-based biomarker platform, the Xerna TME Panel, that used gene expression data and machine learning to classify patients by the dominant biology of their tumor microenvironment, aiming to match cancer patients to clinical-stage therapies with mechanisms addressing those biologies.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded as Oncologie
Oncologie was founded by Laura Benjamin to develop precision oncology guided by RNA-based biomarkers.
- Rebranded to OncXerna
Oncologie announced new clinical data from its bavituximab and navicixizumab programs and rebranded as OncXerna Therapeutics, reflecting its focus on the RNA-based approach.
- Exact Sciences licensing deal
Exact Sciences licensed the Xerna TME Panel to include it in its GEM ExTra genomic profiling test, with plans to offer it to clinicians as a companion diagnostic for immunotherapy response.
- Closed
Crunchbase lists OncXerna Therapeutics' operating status as Closed; no public shutdown announcement or closure date was found.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.